Compare · DHAI vs DXCM
DHAI vs DXCM
Side-by-side comparison of DIH Holdings US Inc. (DHAI) and DexCom Inc. (DXCM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DHAI and DXCM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM carries a market cap of $29.57B.
- Over the past year, DHAI is down 86.0% and DXCM is down 10.6% - DXCM leads by 75.4 points.
- DXCM has hit the wire 26 times in the past 4 weeks while DHAI has been quiet.
- DXCM has more recent analyst coverage (25 ratings vs 0 for DHAI).
- Company
- DIH Holdings US Inc.
- DexCom Inc.
- Price
- $0.79-56.51%
- $76.59+5.15%
- Market cap
- -
- $29.57B
- 1M return
- +0.00%
- +25.71%
- 1Y return
- -85.97%
- -10.56%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2024
- 2005
- News (4w)
- 0
- 26
- Recent ratings
- 0
- 25
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest DHAI
- DIH Holdings US Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- DIH Holdings US Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Unregistered Sales of Equity Securities
- DIH Holdings US Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- SEC Form 10-K filed by DIH Holdings US Inc.
- DIH Holdings US Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- DIH Announces Fiscal 2025 Fourth Quarter and Fiscal Year End Financial Results
- DIH Holdings US Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
- DIH Holding US, Inc. Announces Reverse Stock Split of its Series A Common Stock
- DIH Holdings US Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- DIH Holdings US Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits
Latest DXCM
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
- Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
- Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
- Director Altman Steven R was granted 5,565 shares (SEC Form 4)
- Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)
- Director Malady Kyle was granted 5,575 shares, increasing direct ownership by 25% to 28,242 units (SEC Form 4)
- Director Heller Bridgette P was granted 5,575 shares, increasing direct ownership by 22% to 30,582 units (SEC Form 4)
- Director Osterloh Albert Frederick Iv was granted 1,630 shares, increasing direct ownership by 23% to 8,691 units (SEC Form 4)
- Director Foletta Mark G was granted 6,331 shares (SEC Form 4)